Overview

* Solid Biosciences reports Q2 2025 net loss of $39.5 mln, up from Q2 2024

* R&D expenses rose due to increased costs for SGT-003 program

* Company ended Q2 2025 with $268.1 mln in cash, runway into H1 2027

Outlook

* Company to discuss SGT-003 regulatory pathways with FDA in Q4 2025

* Company expects SGT-212 Phase 1b trial initiation in Q4 2025

* SGT-501 Phase 1b trial initiation expected in Q4 2025

* Solid anticipates cash runway into H1 2027

Result Drivers

* INCREASED R&D EXPENSES - R&D expenses rose due to manufacturing, regulatory, and clinical costs for SGT-003

* CASH POSITION - Company ended Q2 with $268.1 mln in cash

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.42

Q2 Net -$39.50

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Solid Biosciences Inc ( SLDB ) is $16.00, about 62% above its August 11 closing price of $6.08

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)